Eli Lilly 미래 성장

Future 기준 확인 5/6

Eli Lilly (는) 각각 연간 29.5% 및 17.9% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 30% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 57.4% 로 예상됩니다.

주요 정보

29.5%

수익 성장률

30.0%

EPS 성장률

Pharmaceuticals 수익 성장	0%
매출 성장률	17.9%
향후 자기자본 수익률	57.4%
애널리스트 커버리지	Good
마지막 업데이트	12 Nov 2024

최근 미래 성장 업데이트

Recent updates

수익 및 매출 성장 예측

SNSE:LLY - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	69,852	24,938	18,304	22,415	25
12/31/2025	58,294	19,640	12,124	17,288	28
12/31/2024	45,653	11,307	8,684	11,901	27
9/30/2024	40,863	8,370	-1,744	6,032	N/A
6/30/2024	38,923	7,342	-2,024	4,510	N/A
3/31/2024	35,932	6,138	-2,292	3,676	N/A
12/31/2023	34,124	5,240	-1,548	4,240	N/A
9/30/2023	32,073	4,988	1,469	6,215	N/A
6/30/2023	29,516	6,498	3,307	6,242	N/A
3/31/2023	27,691	5,687	3,881	6,793	N/A
12/31/2022	28,541	6,245	4,696	7,586	N/A
9/30/2022	29,240	6,033	5,404	8,080	N/A
6/30/2022	29,071	5,692	4,950	7,494	N/A
3/31/2022	29,323	6,129	5,824	8,086	N/A
12/31/2021	28,318	5,582	5,604	7,366	N/A
9/30/2021	27,759	5,972	4,621	6,919	N/A
6/30/2021	26,726	6,071	4,837	7,095	N/A
3/31/2021	25,486	6,093	5,565	7,815	N/A
12/31/2020	24,540	6,194	4,471	6,500	N/A
9/30/2020	23,214	5,573	5,112	6,648	N/A
6/30/2020	22,950	5,618	4,890	6,352	N/A
3/31/2020	23,087	5,533	3,684	4,908	N/A
12/31/2019	22,320	4,638	3,483	4,837	N/A
9/30/2019	21,843	4,264	2,671	4,322	N/A
6/30/2019	21,673	4,103	3,324	4,933	N/A
3/31/2019	21,622	2,545	2,217	5,399	N/A
12/31/2018	21,493	3,151	2,506	5,525	N/A
9/30/2018	22,016	372	2,100	5,819	N/A
6/30/2018	22,368	-166	N/A	5,579	N/A
3/31/2018	22,607	1,074	N/A	5,712	N/A
12/31/2017	19,974	-86	N/A	5,616	N/A
9/30/2017	22,471	2,225	N/A	5,879	N/A
6/30/2017	22,005	2,447	N/A	5,659	N/A
3/31/2017	21,585	2,187	N/A	5,410	N/A
12/31/2016	21,222	2,738	N/A	4,851	N/A
9/30/2016	20,837	2,444	N/A	3,841	N/A
6/30/2016	20,605	2,466	N/A	3,284	N/A
3/31/2016	20,179	2,319	N/A	2,830	N/A
12/31/2015	19,959	2,408	N/A	2,965	N/A
9/30/2015	19,704	2,359	N/A	3,318	N/A
6/30/2015	19,620	2,059	N/A	3,905	N/A
3/31/2015	19,577	2,192	N/A	4,010	N/A
12/31/2014	19,616	2,391	N/A	4,458	N/A
9/30/2014	20,303	2,690	N/A	4,744	N/A
6/30/2014	21,200	3,392	N/A	5,045	N/A
3/31/2014	22,194	3,865	N/A	5,628	N/A
12/31/2013	23,113	4,685	N/A	5,735	N/A

애널리스트 미래 성장 예측

수입 대 저축률: LLY 의 연간 예상 수익 증가율( 29.5% )이 saving rate( 5.5% 보다 높습니다. ).

수익 vs 시장: LLY 의 연간 수익( 29.5% ) CL 시장( 11.4% 보다 빠르게 성장할 것으로 예상됩니다. 11.4% 연간).

고성장 수익: LLY 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: LLY 의 수익(연간 17.9% ) CL 시장( 5.8% 보다 빠르게 성장할 것으로 예상됩니다. 5.8% 연간).

고성장 수익: LLY 의 수익(연간 17.9% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: LLY 의 자본 수익률은 3년 내에 매우 높을 것으로 예상됩니다( 57.4 %).

Eli Lilly 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Recent updates

Eli Lilly and Company Announces Detailed Results from the Phase 3 Survey-1 Three-Year Study

Eli Lilly and Company Announces Details of Presentations At the 2024 American Society of Hematology Annual Meeting

Third quarter dividend of US$1.30 announced

Eli Lilly and Company to Present Results from Phase 3 EMBER-3 Study of Imlunestrant, an Oral SERD, and Additional Results from Its Breast Cancer Portfolio at the San Antonio Breast Cancer Symposium

Third quarter 2024 earnings released: EPS: US$1.08 (vs US$0.064 loss in 3Q 2023)

Eli Lilly and Company Revises Earnings Guidance for the Year 2024

Lilly's Mirikizumab Is First and Only IL23p19 Antagonist to Report Long-Term, Multi-Year, Sustained Efficacy and Safety Data for Both Ulcerative Colitis and Crohn's Disease

Eli Lilly and Company Declares Fourth-Quarter 2024 Dividend, Payable on December 10, 2024

Lilly's EBGLYSS (Lebrikizumab-Lbkz) Demonstrated Meaningful Improvement in Skin Clearance and Itch Relief in the Majority of Patients with Moderate-To-Severe Atopic Dermatitis Who Discontinued Dupilumab

Eli Lilly and Company to Report Q3, 2024 Results on Oct 30, 2024

Eli Lilly and Company Reports One-Year Histologic Outcomes in Phase 3 Study of Mirikizumab Compared to Ustekinumab for Crohn's Disease

Eli Lilly and Company Appoints Thomas J. Fuchs as First Chief AI Officer, Effective October 21, 2024

FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis

Eli Lilly and Co. Appoints Lucas Montarce as CFO

Eli Lilly and Company Announces Positive Topline Results from the QWINT-1 and QWINT-3 Phase 3 Clinical Trials Evaluating Once Weekly Insulin Efsitora Alfa

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Positive Topline Results from the Surmount-1 Three-Year Study Evaluating the Efficacy and Safety of Tirzepatide

Eli Lilly and Company Announces Retirement of Marschall S. Runge as Independent Director, Effective August 31, 2024

Eli Lilly and Company (NYSE:LLY) completed the acquisition of Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others.

Second quarter 2024 earnings released: EPS: US$3.29 (vs US$1.96 in 2Q 2023)

Eli Lilly and Company Raises Earnings Guidance Full-Year 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company to Report Q2, 2024 Results on Aug 08, 2024

Eli Lilly and Company (NYSE:LLY) entered into an agreement and plan of merger to acquire Morphic Holding, Inc. (NasdaqGM:MORF) from TAS Partners, LLC, Timothy Springer, Chafen Lu and others for $3.2 billion.

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견